• Dopamine is a neurotransmitter that plays a critical role in the control of movement1,2
  • It acts as an excitatory neurotransmitter at some receptors, and is inhibitory at others1,2
  • Neurons containing dopamine are clustered in the substantia nigra of the midbrain – the region most prominently damaged by PD1,2
  • The pars compacta region of the SNc modulates the activity of the striatum, via the neurotransmitter, dopamine – this modulation is critical in the control of body movement1,2

PD=Parkinson’s disease; SNc=substantia nigra 

file_download Download in HQ

Related content

image Image Graphic showing extracellular, multimerization, and intracellular targets of alpha-synuclein for therapeutic intervention in Parkinson’s disease
Possible α-synuclein targets for development of therapies for Parkinson’s disease

Overview of three therapeutic strategies targeting alpha-synuclein in the development of disease-modifying treatments for Parkinson’s disease

26.06.2025 Parkinson’s Disease
image Image Chart showing progression of functional decline in Parkinson’s disease with different treatment approaches, from symptomatic benefit to disease modification.
Disease modification in Parkinson’s disease

Graphical representation of how various treatment strategies can impact disease progression in Parkinson’s disease, from symptom relief to potential cure

26.06.2025 Parkinson’s Disease
image Image Diagram showing how COMT inhibitors block the conversion of L-DOPA to 3-OMD, enhancing dopamine levels in the synapse in Parkinson’s disease.
Catechol-O-methyltransferase (COMT) inhibitors mechanism of action

Illustration of how COMT inhibitors increase dopamine availability in Parkinson’s disease by preventing the breakdown of L-DOPA

26.06.2025 Parkinson’s Disease